Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
  • Records
  • Legit.Health Plus Version 1.1.0.0
  • Legit.Health Plus Version 1.1.0.1
  • Legit.Health version 2.1 (Legacy MDD)
  • Legit.Health Utilities
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • BSI Non-Conformities
    • Technical Review
    • Clinical Review
      • Round 1
        • Item 0: Background & Action Plan
        • Item 1: CER Update Frequency
        • Item 2: Device Description & Claims
        • Item 3: Clinical Data
        • Item 4: Usability
        • Item 5: PMS Plan
        • Item 6: PMCF Plan
        • Item 7: Risk
        • MDCG 2020-13 & CER Template (reference)
          • MDCG 2020-13 (CEAR) sections
            • 00 Front matter, introduction, scope, approach
            • Section A — Administrative particulars
            • Section B — Reviewers involved in the notified body assessment
            • Section C (part 1) — Device description and classification
            • Section C (part 2) — CEP, information materials, common specifications, equivalence, state of the art
            • Section D — Clinical literature review
            • Section E — Clinical investigations and related documentation
            • Section F — PMS, PMCF and the plan for updates
            • Section G — IFU, SSCP, labelling and other information supplied with the device
            • Section I — Clinical evaluation consultation procedure (Article 54)
            • Section J — Where demonstration of conformity based on clinical data is not deemed appropriate (Article 61(10))
            • Section K — The voluntary clinical consultation on the clinical development strategy (Article 61(2))
            • Overall Conclusions
          • CER Template sections
        • Adequacy review
        • Coverage matrix
        • task-3b2-3b3-legacy-rwe-study
        • task-3b4-mrmc-dark-phototypes
  • Pricing
  • Public tenders
  • BSI Non-Conformities
  • Clinical Review
  • Round 1
  • MDCG 2020-13 & CER Template (reference)
  • MDCG 2020-13 (CEAR) sections
  • Section A — Administrative particulars

Section A — Administrative particulars

Source: MDCG-2020-01.pdf page 6 (document: MDCG 2020-13, Clinical evaluation assessment report template, July 2020)

Template CEAR​

Section A: Administrative particulars (notified body, manufacturer, product and clinical evaluation report reference)

Device and manufacturer identification​

FieldValue
Medical device name model and type_____
Project number_____
Risk Class_____
Applicable code(s) per Commission Implementing Regulation (EU) 2017/2185_____
Manufacturer(s) name and SRN_____
Authorised representative (if applicable) name and SRN_____
Intended purpose_____
  • Basic UDI-DI(s) (if available): _____
  • Certificate number (if applicable): _____

Notified body contact​

FieldValue
Notified body_____
Notified body number_____
E-mail contact of NB_____
Telephone contact of NB_____

Type of assessment​

  • Initial conformity assessment
  • Assessment of changes1 and update of the clinical evaluation2
  • Re-certification assessment
  • Assessment of technical documentation for class IIa / IIb devices on a sampling basis

Check of clinical evaluation report authors​

  • CER dated and signed
  • CVs provided for CER author(s)

Comments:

Confirm CVs are up to date

Confirm CER authors have full range of required expertise represented (e.g. research methods, information

Parts of this template which have been applied​

General considerations3

  • Section A: Administrative particulars
  • Section B: Reviewers involved
  • Section C: Device description, classification, clinical evaluation plan, information materials supplied by the manufacturer, common specifications and harmonised standards applied, equivalence and state of the art
  • Section D: Clinical literature review
  • Section E: Clinical investigations and related documentation
  • Section F: PMS and PMCF
  • Section G: IFU, SSCP, labelling and other information supplied with the device
  • Section H: Summary of all available data and conclusions
  • Overall Conclusions

Specific Considerations

Footnotes​

  1. MDR, Annex IX Section 4.10 ↩

  2. For example in accordance with Annex VII, Section 4(10) ↩

  3. These must be completed in all cases ↩

Previous
00 Front matter, introduction, scope, approach
Next
Section B — Reviewers involved in the notified body assessment
  • Template CEAR
    • Device and manufacturer identification
    • Notified body contact
    • Type of assessment
    • Check of clinical evaluation report authors
    • Parts of this template which have been applied
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)